Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

* A Histological or cytological confirmed diagnosis of Stage III-IV NSCLC, with no history of anticancer treatment including chemotherapy;
* Male or female aged 18-75years;
* Eastern Cooperative Oncology Group (ECOG) performance score 0-2;
* Life expectancy of at least 3 months;
* At least one radiographically measurable lesion per RECIST 1.1;
* Willing to join the clinic trail and sign informed consent;
* Able to comply with scheduled visits and treatments.

Exclusion Criteria:

* Presence of cerebral metastases;
* Confirmed positive for expression of expression of epidermal growth factor receptor (EGFR), activin receptor-like kinase (ALK), c-ros oncogene 1 (ROS1) mutation, or programmed death-ligand 1 (PD-L1)(tumor proportion score \[TPS≥ 50%\] in a genetic test;
* Participants with malignant pleural effusion underwent intrapleural injection chemotherapy;
* Current undergoing or preparing for treatment with target therapy;
* Current undergoing or preparing for radiotherapy to the thorax;
* Current undergoing or preparing treatment with tumor immunotherapy;
* Currently undergoing lipid-decreasing treament;
* Pregnant or breastfeeding woman;
* Fertile patients who are unwilling or unable to take effective contraceptive measures during the research period until 6 months after the study end later;
* A history of mental disorders；
* Severe and uncontrolled organic lesion or infection, including but not limited to cardiopulmonary failure and renal failure，which lead to poor tolerance of chemotherapy;
* Participated in other clinical trials of small molecule research drugs within 28 days prior to enrollment, or participated in other clinical trials of large molecule research drugs within 3 months before enrollment;
* Known allergy or intolerance to study medications;
* Considered to be otherwise unsuitable for the clinical study by researchers.